Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05262036
Other study ID # NS-1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 4, 2022
Est. completion date December 31, 2023

Study information

Verified date October 2023
Source Integrative Skin Science and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the use of an oral supplement to see if it can shift the function of the skin and the appearance of fine lines and wrinkles, its impact on biomarkers associated with aging, and its impact on mental health.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 38
Est. completion date December 31, 2023
Est. primary completion date August 9, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 70 Years
Eligibility Inclusion Criteria: - Female and male subjects - Subjects who are between the ages of 35 to 70. - Subjects must be able to read and comprehend study procedure and consent forms - Must be willing to comply with all protocol requirements - Must be willing to have facial photographic images taken Exclusion Criteria: - Women who have been pregnant in the last three months, currently pregnant, preparing to become pregnant during the study, or breastfeeding. - Individuals who have a history of smoking or chewing tobacco or vaping nicotine based product within the past year or if the pack-year history of smoking tobacco is greater than 5 pack-years. - Those that have undergone a change in hormone-based therapies such as, but not limited to, oral contraceptive pills or progesterone pills within the last 2 months. Progesterone releasing IUDs are considered hormone-based therapy. Spironolactone is not considered a hormone-based therapy. - Subjects who are unwilling or unable to comply with the requirements of the protocol. - Subjects who have a history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study in the opinion of the principal investigator. - Has a skin disease on the face that will interfere with image collection and assessment in the opinion of the investigator. - History of any significant chronic disease including endocrine, inflammatory, cardiovascular, renal, liver, gastro-intestinal, psychiatric, neurological, neoplastic, or metabolic disease for at least 90 days prior to screening. Clinical significance of active disease will be assessed by the Qualified Investigator to determine eligibility. - Subjects with or who have recently experienced traumatic injury, infections, or major surgery at the discretion of the Qualified Investigator. - Subjects who are likely to start taking drugs/medication on a chronic basis or that will undergo surgery during the trial. - Subjects engaged in donation or who were recipients of blood products within 90 days before the start of the study. - Subjects with alcohol use of more than 2 alcoholic beverages per day within the past month. - Subjects participated in a clinical trial with a medicinal, supplemental, nutraceutical or drug within the past two months prior to the first dose in the current study. - Use of lipid, cholesterol and/or blood-sugar lowering agents (e.g. statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, prescription-based nicotinic acid derivatives (e.g. niacin extended release), metformin, sulfonylureas, including fish oil). If participants take fish oil supplements, they will be asked to stop taking these supplements 21 days before the start of trial and during the trial. - Subjects using anti-inflammatory drugs on a chronic basis (e.g. aspirin, ibuprofen, diclofenac, celecoxib, etc). - Subjects using supplements or substances present in formulation (malate, fisetin, glucosamine, alpha ketoglutaric acid, glycine, theanine, Rhodiola rosea, hyaluronic acid, ginger extract, pterostilbene, lithium). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial. - Subjects using supplements or substances similar as those used in the formulation (e.g. resveratrol (similar to pterostilbene) or quercetin (similar to fisetin)). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial. - Subjects taking NAD boosters, like NMN, nicotinamide riboside (NR), high-dose niacin (nicotinic acid), high-dose vitamin B3, high-dose nicotinamide (niacinamide) within 21 days before the start of the trial. Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial. - Subjects taking supplements or drugs or nutraceuticals to improve skin, such as hyaluronic acid, collagen, chondroitin, glucosamine. Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial. - Subjects with clinically significant abnormal laboratory results at screening.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Anti-aging Supplement
Mixture of different vitamins and nutrients
Placebo
Excipient powder

Locations

Country Name City State
United States Integrative Skin Science and Research Sacramento California

Sponsors (2)

Lead Sponsor Collaborator
Integrative Skin Science and Research AgeLess Sciences Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Appearance of Fine Lines and Wrinkles Fine lines and wrinkles measured by high resolution photography (BTBP Clarity Pro) to measure wrinkle severity (combines depth and width). Measured by computer calculation. 6 months
Secondary Appearance of facial redness Change in the appearance of facial redness by high resolution photography (BTBP Clarity Pro) and measures intensity of facial redness. Measured by computer calculation 6 months
Secondary Appearance of facial pigmentation Change in the appearance of facial pigmentation by high resolution photography (BTBP Clarity Pro) and measures intensity of facial pigmentation. Measured by computer calculation 6 months
Secondary Appearance of facial texture Change in the appearance of facial texture by high resolution photography (BTBP Clarity Pro) and measures evenness of skin surface. Measured by computer calculation 6 months
Secondary Skin hydration Skin hydration measured by non-invasive device 6 months
Secondary Skin elasticity Skin viscoelasticity measured by non-invasive device 6 months
Secondary Fasting lipids Change in fasting lipids (LDL, HDL) 6 months
Secondary Hemoglobin A1c Change in Hemoglobin A1c 6 months
Secondary Ultra-sensitive CRP Change in ultra-sensitive CRP 6 months
Secondary Blood pressure Change in blood pressure (diastolic and systolic) 6 months
Secondary Mental health survey Assessment of mental health status by survey 6 months
Secondary Subjective skin health survey Subjective assessment of skin health by survey 6 months
Secondary Epigenetic signals Evaluation of epigenetic expression changes 6 months
See also
  Status Clinical Trial Phase
Completed NCT05271136 - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum N/A
Completed NCT05514782 - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum N/A
Completed NCT04911374 - An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream N/A
Completed NCT04586816 - Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging N/A
Not yet recruiting NCT05004909 - Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream N/A
Completed NCT05039723 - Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational Phase 4
Completed NCT06366503 - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation N/A
Completed NCT05027282 - Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment N/A
Not yet recruiting NCT06096649 - The Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged Skin N/A
Completed NCT03661697 - Combination Versus Laser Treatment Only N/A
Completed NCT03948945 - Efficacy and Safety of Profile HaloTM Mixed Fractional Laser on Treating of Facial and Neck Photoaging. N/A
Completed NCT06148558 - A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+ N/A
Enrolling by invitation NCT06188338 - A 56-day Clinical Study on Facial Skin Rejuvenation N/A
Recruiting NCT06195605 - Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin N/A
Not yet recruiting NCT04869852 - Effects of Mango Intake on Skin Health and Gut Microbiome Changes in Postmenopausal Women N/A
Not yet recruiting NCT02126644 - The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging Phase 2
Active, not recruiting NCT01372566 - Effect of Platelet Rich Plasma on Photoaged Skin Phase 1/Phase 2
Unknown status NCT00842907 - Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage Phase 2
Completed NCT03112863 - Comparison of the Cosmetic Effects of Bakuchiol and Retinol Early Phase 1
Recruiting NCT05386368 - RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients Phase 4